Skip to main content
SpringerLink
Log in

Calcium Overload — An Important Cellular Mechanism in Hypertension and Arteriosclerosis

  • Published:
Drugs Aims and scope Submit manuscript

Summary

Arterial hypertension and arteriosclerosis are dramatic consequences of vascular calcium overload. Acute intracellular calcium overload of vascular smooth muscle cells produces hypercontractility. Hypertension develops if a general increase in systemic arteriolar tone leads to a rise in peripheral flow resistance. Moreover, progressive elevation of calcium destroys the structural integrity of the arterial and arteriolar walls. Thus, in various animal models, calcium overload initiates lesions of an arteriosclerotic character. Interestingly, conventional human coronary plaques also represent a calcium-dominated type of arteriosclerosis.

With the advent of specific calcium antagonists, the pathogenic effects of calcium overload and its deleterious consequences have become, for the first time, accessible to therapeutic intervention. Accordingly, adequate treatment with calcium antagonists prevents calcium overload and can thereby protect arteries and arterioles from functional disturbances and structural damage. In spontaneously hypertensive rats, specific calcium antagonists of the verapamil, nifedipine and diltiazem type normalise blood pressure (BP) by reducing transmembrane calcium influx into vascular smooth muscle cells. However, in addition to controlling BP, these drugs also act as tissue protective agents. The long term effects of calcium antagonists such as verapamil in experimental hypertension include the prevention of severe arteriosclerosis, myocardial hypertrophy, and malignant nephrosclerosis. In humans, the antihypertensive efficacy of verapamil is well documented. Further clinical studies have yet to evaluate the antiarteriosclerotic and tissue protective potential of verapamil in humans.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aoki K. Three-way classification of hypertension: gene hypertension, environment hypertension, and disease hypertension. In Aoki K (Ed.) Essential hypertension 2, pp. 9–33, Springer-Verlag, Tokyo, 1989

    Chapter  Google Scholar 

  • Baudouin-Legros M, Meyer P. Hypertension and atherosclerosis. Journal of Cardiovascular Pharmacology 15(Suppl. 1): S1–S6, 1990

    PubMed  Google Scholar 

  • Czirfusz A, Fleckenstein-Grün G. Increased ‘leak’ and stimulated (by K-rich solution and endothelin 2) net 45Ca uptake into aortic media cells of SHRs compared to WKY. Naunyn-Schmiedebergs Archives of Pharmacology 344(Suppl. 2): R105, 1991

    Google Scholar 

  • Fleckenstein A. Specific inhibitors and promoters of calcium action in the excitation-contraction coupling of heart muscle and their role in the prevention or production of myocardial lesions. In Harris P, Opie L (Eds) Calcium and the heart. Proceedings of the Meeting of the Europe Section of the International Study Group for Research in Cardiac Metabolism, London, Sep 1970, pp. 135–188, Academic Press, London, 1971

    Google Scholar 

  • Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annual Review of Pharmacology and Toxicology 17: 149–166, 1977

    Article  PubMed  CAS  Google Scholar 

  • Fleckenstein A. History of calcium antagonists. In Schwartz A, Taira N (Eds) Calcium channel blocking drugs: a novel intervention for the treatment of cardiac disease, Monograph No. 95 of the American Heart Association. Circulation Research 52(Part II): 3–16, 1983a

    CAS  Google Scholar 

  • Fleckenstein A. Calcium antagonism in heart and smooth muscle–experimental facts and therapeutic prospects. Monograph, John Wiley Publishing Company, New York, 1983b

    Google Scholar 

  • Fleckenstein A, Fleckenstein-Grün G. Cardiovascular protection by Ca antagonists. European Heart Journal 1: 15–21, 1980

    PubMed  CAS  Google Scholar 

  • Fleckenstein A, Fleckenstein-Grün G, Frey M, Zorn J. Future directions in the use of calcium antagonists. American Journal of Cardiology 59: 177B–187B, 1987a

    Article  PubMed  CAS  Google Scholar 

  • Fleckenstein A, Frey M, Fleckenstein-Grün G. Protection by calcium antagonists against experimental arterial calcinosis. In Pyörälä K, et al. (Eds) Secondary prevention of coronary heart disease. Workshop of the International Society and Federation of Cardiology, Titisee, Oct 1983, pp. 109–122, Thieme Verlag, Stuttgart, 1983

    Google Scholar 

  • Fleckenstein A, Frey M, Fleckenstein-Grün G. Antihypertensive and arterial anticalcinotic effects of calcium antagonists. American Journal of Cardiology 57: 1D–10D, 1986

    Article  PubMed  CAS  Google Scholar 

  • Fleckenstein A, Frey M, Thimm F, Fleckenstein-Grün G. Excessive mural calcium overload–a predominant causal factor in the development of stenosing coronary plaques in humans. Cardiovascular Drugs and Therapy 4: 1005–1014, 1990b

    Article  PubMed  Google Scholar 

  • Fleckenstein A, Frey M, Zorn J, Fleckenstein-Grün G. Experimental basis of the long-term therapy of arterial hypertension with calcium antagonists. American Journal of Cardiology 56: 3H–14H, 1985

    Article  PubMed  CAS  Google Scholar 

  • Fleckenstein A, Frey M, Zorn J, Fleckenstein-Grün G. The role of calcium in the pathogenesis of experimental arteriosclerosis. Trends in Pharmacological Sciences 8: 496–501, 1987b

    Article  CAS  Google Scholar 

  • Fleckenstein A, Frey M, Zorn J, Fleckenstein-Grün G. Calcium, a neglected key factor in hypertension and arteriosclerosis. Experimental vasoprotection with calcium antagonists or ACE inhibitors. In Laragh JH, Brenner BM (Eds) Hypertension: pathophysiology, diagnosis, and management, pp. 471–509, Raven Press, New York, 1990a

    Google Scholar 

  • Fleckenstein A, Kammermeier H, Döring HJ, Freund HJ, Grün G, et al. Zum Wirkungsmechanismus neuartiger Koronardilatatoren mit gleichzeitig Sauerstoff-einsparenden Myokard-Effekten, Prenylamin und Iproveratril. Zeitschrift für Kreislaufforschung 56: 716–744, 839-858, 1967

    PubMed  CAS  Google Scholar 

  • Fleckenstein-Grün G. Role of transmembrane Ca++ supply in phasic and tonic activation of vascular smooth muscle–vasodilator efficacy of calcium antagonists. In Berman MC, et al. (Eds) Membranes and muscles. Proceedings of an International Symposium in Cape Town, March, 1985. IRL Press, ICSU Symposium Series 6: 235–255, 1985

    Google Scholar 

  • Fleckenstein-Grün G, Fleckenstein A. Calcium antagonism, a basic principle in vasodilation. In Zanchetti A, Krikler DM (Eds) Calcium antagonism in cardiovascular therapy: experience with verapamil. International Symposium in Florence, Italy, Oct 1980, pp. 30–38, Excerpta Medica, Amsterdam, 1981

    Google Scholar 

  • Fleckenstein-Grün G, Fleckenstein A. Calcium–a neglected key factor in arteriosclerosis. The pathogenetic role of arterial calcium overload and its prevention by calcium antagonists. Proceedings of the 1st International Duodecim Symposium inflammation and Atherogenesis’, Tampere/Finland, May 1991. Annals of Medicine 23: 589–599, 1991

    Article  PubMed  Google Scholar 

  • Grün G, Fleckenstein A. Die elektro-mechanische Entkoppelung der glatten Gefassmuskulatur als Grundprinzip der Coronardilatation durch 4-(2′-Nitrophenyl)-2, 6-dimethyl-1, 4-dihydropyridin-3, 5-dicarbonsäure-dimethylester (Bay a 1040, Nifedipin). Arzneimittel-Forschung 22: 334–344, 1972

    PubMed  Google Scholar 

  • Hof RP, Tapparelli C, Weinstein DB. Hemodynamic, antivasoconstrictor, and antiatherosclerotic effects of calcium antagonists in animal models of atherosclerosis. Journal of Cardiovascular Pharmacology 15(Suppl. 1): S7–S12, 1990

    PubMed  CAS  Google Scholar 

  • Janke J, Hein B, Pachinger O, Leder O, Fleckenstein A. Hemmung arteriosklerotischer Gefässprozesse durch prophylaktische Behandlung mit MgCl2, KCl und organischen Ca++-Antagonisten (quantitative Studien mit 45Ca bei Ratten). In Betz E (Ed.) Vascular smooth muscle, verh Satel Symp XXV International Congress of Physiology, Wissenschaften, Tübingen, July 1971, pp. 71–72, Springer-Verlag, Berlin, 1972

    Google Scholar 

  • Koutouzov S, Remmal A, Girard A, Meyer P, Marche P. Increased platelet phospholipase C activity: a molecular basis for the cellular hyperactivity in primary hypertension. In Meyer P, Marche P (Eds) Blood cells and arteries in hypertension and atherosclerosis, pp. 141–156, Raven Press, New York, 1989

    Google Scholar 

  • Resink TJ, Bühler FR. Dysfunctions of calcium extrusion in hypertension. In Meyer P, Marche P (Eds) Blood cells and arteries in hypertension and atherosclerosis, pp. 157–169, Raven Press, New York, 1989

    Google Scholar 

  • Rusch NJ, Hermsmeyer K. Calcium currents are altered in the vascular muscle cell membrane of spontaneously hypertensive rats. Circulation Research 63: 997–1002, 1988

    Article  PubMed  CAS  Google Scholar 

  • Seuwen K, Chambard JC, L’Allemain G, Magnaldo I, Paris S, et al. Thrombin as a growth factor: mechanism of signal transduction. In Meyer P, Marche P (Eds) Blood cells and arteries in hypertension and atherosclerosis, pp. 217–232, Raven Press, New York, 1989

    Google Scholar 

  • Van Breemen C, Saida K. Cellular mechanisms regulating (Ca2+)1 smooth muscle. Annual Review of Physiology 51: 315–319, 1989

    Article  PubMed  Google Scholar 

  • Yamori Y, Nara Y, Shimizu S, Mano M, Nabika T. Common cellular mechanisms in the development of hypertension and atherosclerosis. In Meyer P, Marche P (Eds) Blood cells and arteries in hypertension and atherosclerosis, pp. 233–245, Raven Press, New York, 1989

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Study Group for Calcium Antagonism, Physiological Institute, University of Freiburg, Hermann-Herder-Strasse 7, W-7800, Freiburg, Federal Republic of Germany

    G. Fleckenstein-Grün, M. Frey, F. Thimm, W. Hofgärtner & A. Fleckenstein

Authors
  1. G. Fleckenstein-Grün
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Frey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Thimm
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. Hofgärtner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Fleckenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fleckenstein-Grün, G., Frey, M., Thimm, F. et al. Calcium Overload — An Important Cellular Mechanism in Hypertension and Arteriosclerosis. Drugs 44 (Suppl 1), 23–30 (1992). https://doi.org/10.2165/00003495-199200441-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199200441-00005

Keywords

Search

Navigation